Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field

Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field

Source: 
Fierce Biotech
snippet: 

Roche has bought Inflazome for €380 million ($451 million) upfront to gain control of treatments for inflammatory diseases. The deal gives Roche full rights to a pipeline of oral NLRP3 inhibitors led by two clinical-phase drugs Inflazome is developing as treatments for Parkinson’s and other diseases.